Cochrane · systematic review · CD012007
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
Ngoi, NYL, Syn, NLX, Goh, RM, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 2 · 40%High 2 · 40%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment of ovarian cancer
Population: first‐line treatment of ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression‐free survival (PFS) Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin | HR 0.89 [0.81, 0.98] | 4 studies · 3699 participants | Moderate Downgraded: risk of bias |
Overall survival (OS) Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin | HR 0.92 [0.79, 1.06] | 4 studies · 3699 participants | High |
Haematological adverse event: Grade 3/4 neutropenia Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin | RR 1.11 [0.86, 1.43] | 4 studies · 3639 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Haematological adverse event: Grade 3/4 anaemia Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin | RR 1.57 [1.12, 2.2] | 4 studies · 3639 participants | High |
Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin | RR 1.12 [0.64, 1.94] | 4 studies · 3639 participants | Low Downgraded: risk of bias |